Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Briacell Therapeutics Corp (BCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: BCTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $95
1 Year Target Price $95
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.86% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.98M USD | Price to earnings Ratio - | 1Y Target Price 95 |
Price to earnings Ratio - | 1Y Target Price 95 | ||
Volume (30-day avg) 2 | Beta 1.62 | 52 Weeks Range 6.00 - 190.50 | Updated Date 10/25/2025 |
52 Weeks Range 6.00 - 190.50 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -62.19 |
Earnings Date
Report Date 2025-10-15 | When - | Estimate -12.11 | Actual 0.0443 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -123.56% | Return on Equity (TTM) -362.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9949497 | Price to Sales(TTM) - |
Enterprise Value 9949497 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 1883906 | Shares Floating 1558122 |
Shares Outstanding 1883906 | Shares Floating 1558122 | ||
Percent Insiders 2.34 | Percent Institutions 9.66 |
Upturn AI SWOT
Briacell Therapeutics Corp
Company Overview
History and Background
Briacell Therapeutics Corp. is an immuno-oncology biotechnology company. It focuses on developing immunotherapies that activate the patient's own immune system to fight cancer. Founded to address unmet needs in cancer treatment, Briacell is involved in the development of off-the-shelf personalized cancer immunotherapies based on its proprietary technology.
Core Business Areas
- Cancer Immunotherapy Development: Focuses on developing off-the-shelf personalized cancer immunotherapies based on its proprietary technology. Developing a novel and effective approach to fight cancer by stimulating the body's immune system to target cancer cells.
Leadership and Structure
The leadership team includes individuals with expertise in oncology, immunology, and biotechnology. The company has a typical structure for a biotech firm, with departments dedicated to research and development, clinical trials, and corporate operations. The CEO is typically a key figure, driving the strategic direction and overseeing operations.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is the company's lead candidate for the treatment of advanced breast cancer. There's no confirmed, definitive market share in terms of percentage. Competitors include major pharmaceutical companies with existing breast cancer treatments like Roche (with Herceptin and Perjeta), Novartis, Eli Lilly, and AstraZeneca.
Market Dynamics
Industry Overview
The cancer immunotherapy market is a rapidly growing segment within the pharmaceutical industry. It involves treatments that harness the body's immune system to fight cancer. It is characterized by intense competition, technological advancements, and high regulatory hurdles.
Positioning
Briacell Therapeutics Corp. is a smaller player focusing on personalized immunotherapy. Competitive advantages include proprietary technology and focus on difficult-to-treat cancers.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of USD in the coming years. Briacell is positioned within this large market, targeting a specific niche with its personalized immunotherapy approach.
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy technology
- Focus on personalized cancer treatment
- Potential for breakthrough therapies in difficult-to-treat cancers
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- Dependence on key personnel and proprietary technology
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline to address other cancer types
- Positive clinical trial results leading to regulatory approval
Threats
- Failure to achieve positive clinical trial results
- Competition from established cancer therapies and larger companies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- MRNA
- BMY
- PFE
- JNJ
- AZN
Competitive Landscape
Briacell is a smaller company operating in a landscape dominated by much larger pharmaceutical companies. Its advantage is its proprietary technology, while its disadvantages are limited resources.
Growth Trajectory and Initiatives
Historical Growth: Growth depends on clinical trial progress and successful fundraising. Past performance has been volatile, tied to news related to their pipeline.
Future Projections: Future growth projections are highly dependent on clinical trial outcomes and regulatory approvals. Analyst estimates will vary widely based on perceived risk and potential.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for Bria-IMTu2122 and exploring other immunotherapy candidates.
Summary
Briacell Therapeutics is a high-risk, high-reward biotechnology firm with a focus on personalized cancer immunotherapies. The company's success hinges on positive clinical trial results for its lead candidate, Bria-IMTu2122. They need to successfully navigate the regulatory hurdles and competition from larger pharmaceutical players. The financials are speculative, relying on the clinical trial milestones. Overall, the company has a long way to go to prove that the technology is viable to combat cancer.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Briacell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.